Aurora Spine Corporation Announces Participation at the North American Spine Society Annual Meeting
September 27 2021 - 06:15AM
Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV:
ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative
medical devices that improve spinal surgery outcomes, today
announced it would be participating at the 2021 North American
Spine Society ("NASS") Annual Meeting, September 29-October 2, 2021
at the Boston Convention Center in Boston, Massachusetts at Booth
#1925. The North American Spine Society is a global
multidisciplinary medical society that utilizes education,
research, and advocacy to foster the highest quality, ethical,
value, and evidence-based spine care.
Aurora Spine will showcase its new FDA-cleared DEXA-C anterior
fusion cages used for cervical procedures that use the patented
DEXA technology and offers a series of implants manufactured with
varying modulus values to match patients' bone density and T-Score.
The company will also be highlighting its SiLO™ SI Fusion System,
which surgeons will use to treat patients who require sacroiliac
joint fusion surgery. The system implants a bone allograft into the
SI joint to stabilize and fuse the joint. The company will also be
showcasing its ZIP® products, featuring the Screwless Procedure and
enables MIS Interspinous fusion without using a screw set.
"We are excited to be attending NASS this year in person and
being able to share the many new products Aurora has developed in
the past couple of years, including several for the pain management
market," stated Trent Northcutt, President and Chief Executive
Officer of Aurora Spine & Pain. "As we come out of Covid,
procedures are steadily resuming and more physicians and surgeons
are using our products, which enable them to treat patients with
the most cutting-edge technologies. The Aurora team is looking
forward to a great event and greeting attendees with many new
products and technologies that we have worked diligently to bring
to market in recent years."
"We are excited to share information about our new technologies
at NASS especially the DEXA-C implant line, which we anticipate
will gain much attention as the first product commercialized using
our DEXA Technology patent. The DEXA-C product line is the world’s
first patient-matched interbody implant and is cleared with
multiple modulus ranges that can help treat patients with
less-than-optimal bone quality," said Laszlo Garamszegi, Chief
Technology Officer of Aurora.
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal
implant market through a series of innovative, minimally invasive,
regenerative spinal implant technologies. Additional information
can be accessed at www.aurora-spine.com or
www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that
involves substantial known and unknown risks and uncertainties,
most of which are beyond the control of Aurora Spine, including,
without limitation, those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Information" in
Aurora Spine's final prospectus (collectively, "forward-looking
information"). Forward-looking information in this news release
includes information concerning the proposed use and success of the
company’s products in surgical procedures. Aurora Spine cautions
investors of Aurora Spine's securities about important factors that
could cause Aurora Spine's actual results to differ materially from
those projected in any forward-looking statements included in this
news release. Any statements that express, or involve discussions
as to, expectations, beliefs, plans, objectives, assumptions or
future events or performance are not historical facts and may be
forward-looking and may involve estimates, assumptions and
uncertainties which could cause actual results or outcomes to
differ unilaterally from those expressed in such forward-looking
statements. No assurance can be given that the expectations set out
herein will prove to be correct and, accordingly, prospective
investors should not place undue reliance on these forward-looking
statements. These statements speak only as of the date of this
press release and Aurora Spine does not assume any obligation to
update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent NorthcuttPresident and Chief Executive Officer(760)
424-2004
Chad ClouseChief Financial Officer(760) 424-2004
www.aurora-spine.com
Adam LowensteinerLYTHAM PARTNERS, LLCPhoenix | New
YorkTelephone: 646-829-9700asapf@lythampartners.com
Aurora Spine (TSXV:ASG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aurora Spine (TSXV:ASG)
Historical Stock Chart
From Mar 2023 to Mar 2024